- $20.79m
- $8.98m
- $2.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.28 | ||
| Price to Tang. Book | 3.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -177.76% | ||
| Return on Equity | -154% | ||
| Operating Margin | -931.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 30.11 | 13.98 | 19.28 | 2.59 | 2.03 | 0.77 | 7.94 | -39.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has developed a proprietary drug product for the treatment of ADHD called Methydur.
Directors
- David Hoffmann NEC (76)
- James Brown PRE (64)
- Michael Arenberg CFO (51)
- Judy Joice SVP (64)
- Norman Sussman OTH (68)
- Gail Farfel DRC (57)
- Peter Garcia-Webb DRC (60)
- Mohammad Azab IND (65)
- Simon Benito IND (76)
- Terrence Blaschke IND (78)
- Gail Maderis IND (63)
- Judith Robertson IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 6th, 1998
- Public Since
- September 28th, 2000
- No. of Shareholders
- 69
- No. of Employees
- 21
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 31,041,981
- Address
- 10240 Bubb Road, CUPERTINO, 95014
- Web
- https://www.durect.com/
- Phone
- +1 4087771417
- Contact
- Ashley Robinson
- Auditors
- WithumSmith Brown PC
Upcoming Events for DRRX
Q2 2025 DURECT Corp Earnings Release
Similar to DRRX
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the DURECT share price?
As of Today at 20:19 UTC, shares in DURECT are trading at $0.67. This share price information is delayed by 15 minutes.
How has the DURECT share price performed this year?
Shares in DURECT last closed at $0.67 and the price had moved by -26.89% over the past 365 days. In terms of relative price strength the DURECT share price has underperformed the S&P500 Index by -32.52% over the past year.
What are the analyst and broker recommendations for DURECT?
The overall consensus recommendation for DURECT is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the DURECT dividend yield?
DURECT does not currently pay a dividend.
Does DURECT pay a dividend?
DURECT does not currently pay a dividend.
When does DURECT next pay dividends?
DURECT does not currently pay a dividend.
How do I buy DURECT shares?
To buy shares in DURECT you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of DURECT?
As of the previous close price of $0.67, shares in DURECT had a market capitalisation of $20.79m.
Where are DURECT shares listed?
Here are the trading details for DURECT:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DRRX
What kind of share is DURECT?
Based on an overall assessment of its quality, value and momentum DURECT is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a DURECT share price forecast for 2025?
The analyst consensus target price for shares in DURECT is $6.75. That is 908.06% above the last closing price of $0.67.
Analysts covering DURECT currently have a consensus Earnings Per Share (EPS) forecast of -$0.55 for the next financial year.
Find out moreWhat is the trend in the DURECT share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DURECT. Over the past six months, its share price has underperformed the S&P500 Index by -50.65%.
As of the last closing price of $0.67, shares in DURECT were trading -38.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the DURECT PE Ratio?
The DURECT PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of DURECT?
DURECT's management team is headed by:
- David Hoffmann - NEC
- James Brown - PRE
- Michael Arenberg - CFO
- Judy Joice - SVP
- Norman Sussman - OTH
- Gail Farfel - DRC
- Peter Garcia-Webb - DRC
- Mohammad Azab - IND
- Simon Benito - IND
- Terrence Blaschke - IND
- Gail Maderis - IND
- Judith Robertson - IND